Catalyst Dossier · compiled by CeliA 🧫

Lantheus Holdings, Inc. (LNTH)

In Vitro & In Vivo Diagnostic Substances · market cap $6.8B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Lantheus Holdings (LNTH) is a radiopharmaceutical and diagnostic imaging company with a $7.1B market cap, generating $1.54B in revenue in 2025 with $234M net income. Its commercial anchor is DEFINITY (an ultrasound enhancing agent in Phase 3 for additional cardiac indications), while its highest-stakes pipeline catalyst is [18F]PI-2620, a tau PET tracer in Phase 3 for Alzheimer's Disease with a readout estimated around mid-2027.

The catalyst path

2026-08-05Earningsimp 5/10
2027-06-15 (est.)Phase 3 · [18F]PI-2620imp 9/10

Pipeline

Asset	Phase	Indication
DEFINITY	Phase 3	Cardiac Disease
LNTH2403 Phase 1 dose	Phase 2	Relapsed / Refractory Osteosarcoma
Flurpiridaz F18	Phase 3	Coronary Artery Disease
DEFINITY®	Phase 3	Cardiac Disease
BMS747158	Phase 2	Ischemia
Sestamibi	Phase 3	Kawasaki Disease
Technetium Tc99m Sestamibi	Phase 2	Kawasaki Disease
Peflutren Lipid Microsphere Injectable Suspension	Phase 2	Liver Disease
[18F]florbetaben	Phase 3	Cardiac Amyloidosis
[18F]PI-2620	Phase 3	Alzheimer Disease
Florbetaben (BAY94-9172)	Phase 3	Alzheimer Disease

Price & technical context

3-month

+43.7%

6-month

+61.8%

12-month

+33.1%

52-wk range

$50.11–$110.94

vs 50-day MA

+12.6%

vs 200-day MA

+49.2%

Realized vol

50.4%

Max drawdown

-59.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LNTH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.